Figure 4. Vactosertib inhibits pulmonary metastatic mouse OS development in vivo.

A) Experimental design. BALB/c mice were inoculated with 1×10⁶ K7M2-Luc (i.v.) on day 0, and then treated with vehicle (p.o) or Vactosertib (25 mg/kg p.o. 5 days/week) starting on day 7. B) Bioluminescence image intensity (BLI) was measured once a week. C) Graph of BLI over time. n=5, ***p<0.001 using two-way ANNOVA between groups followed by post-hoc Bonferroni’s comparison tests. D) Relative mRNA expression of GP70, and c-Myc in the lung samples of vehicle or Vactosertib treated mice on day 42 days after tumor injection compared with control lung with no tumor bearing mice. n=5/group, *p<0.05 using an unpaired two-tailed t-test. E) Representative H&E staining of lung of vehicle or Vactosertib treated lung samples day 42 day after tumor injection. Scale bar = 5 mm.